Characterization of Molecular Mechanisms Underlying Mutations in Dystrophic Epidermolysis Bullosa Using Site-directed Mutagenesis*

Type VII collagen (C7) is a major component of anchoring fibrils, structures that mediate epidermal-dermal adherence. Mutations in gene COL7A1 encoding for C7 cause dystrophic epidermolysis bullosa (DEB), a genetic mechano-bullous disease. The biological consequences of specific COL7A1 mutations and the molecular mechanisms leading to DEB clinical phenotypes are unknown. In an attempt to establish genotype-phenotype relationships, we generated four individual substitution mutations that have been associated with recessive DEB, G2049E, R2063W, G2569R, and G2575R, and purified the recombinant mutant proteins. All mutant proteins were synthesized and secreted as a 290-kDa mutant C7 α chain at levels similar to wild type C7. The G2569R and G2575R glycine substitution mutations resulted in mutant C7 with increased sensitivity to protease degradation and decreased ability to form trimers. Limited proteolytic digestion of mutant G2049E and R2063W proteins yielded aberrant fragments and a triple helix with reduced stability. These two mutations next to the 39-amino acid helical interruption hinge region caused local destabilization of the triple-helix that exposed an additional highly sensitive proteolytic site within the region of the mutation. Our functional studies demonstrated that C7 is a potent pro-motility matrix for skin human keratinocyte migration and that this activity resides within the triple helical domain. Furthermore, G2049E and R2063W mutations reduced the ability of C7 to support fibroblast adhesion and keratinocyte migration. We conclude that known recessive DEB C7 mutations perturb critical functions of the C7 molecule and likely contribute to the clinical phenotypes of DEB patients.

[1]  Wei Li,et al.  Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  J. R. McMillan,et al.  Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients. , 2006, The Journal of investigative dermatology.

[3]  J. Uitto,et al.  Epidermolysis bullosa. II. Type VII collagen mutations and phenotype–genotype correlations in the dystrophic subtypes , 2006, Journal of Medical Genetics.

[4]  Hidetoshi Ito,et al.  Single Amino Acid Substitutions in Procollagen VII Affect Early Stages of Assembly of Anchoring Fibrils* , 2005, Journal of Biological Chemistry.

[5]  J. McGrath,et al.  Genotype-phenotype correlation in italian patients with dystrophic epidermolysis bullosa. , 2002, The Journal of investigative dermatology.

[6]  Mei Chen,et al.  The Recombinant Expression of Full-length Type VII Collagen and Characterization of Molecular Mechanisms Underlying Dystrophic Epidermolysis Bullosa* , 2002, The Journal of Biological Chemistry.

[7]  D. Keene,et al.  The Carboxyl Terminus of Type VII Collagen Mediates Antiparallel Dimer Formation and Constitutes a New Antigenic Epitope for Epidermolysis Bullosa Acquisita Autoantibodies* , 2001, The Journal of Biological Chemistry.

[8]  Mei Chen,et al.  α2β1 Integrin Mediates Dermal Fibroblast Attachment to Type VII Collagen via a 158-Amino-Acid Segment of the NC1 Domain , 1999 .

[9]  J. Uitto,et al.  Mutation analysis and molecular genetics of epidermolysis bullosa. , 1999, Matrix biology : journal of the International Society for Matrix Biology.

[10]  M. Raghunath,et al.  Some, but Not All, Glycine Substitution Mutations inCOL7A1 Result in Intracellular Accumulation of Collagen VII, Loss of Anchoring Fibrils, and Skin Blistering* , 1998, The Journal of Biological Chemistry.

[11]  C. Bodemer,et al.  Characterization of 18 new mutations in COL7A1 in recessive dystrophic epidermolysis bullosa provides evidence for distinct molecular mechanisms underlying defective anchoring fibril formation. , 1997, American journal of human genetics.

[12]  C. N. Rao,et al.  Interactions of the Amino-terminal Noncollagenous (NC1) Domain of Type VII Collagen with Extracellular Matrix Components , 1997, The Journal of Biological Chemistry.

[13]  H. L. Li,et al.  Ultraviolet A irradiation upregulates type VII collagen expression in human dermal fibroblasts. , 1997, The Journal of investigative dermatology.

[14]  J. Uitto,et al.  Glycine substitutions in the triple-helical region of type VII collagen result in a spectrum of dystrophic epidermolysis bullosa phenotypes and patterns of inheritance. , 1996, American journal of human genetics.

[15]  L. Bruckner-Tuderman,et al.  Immunohistochemical and mutation analyses demonstrate that procollagen VII is processed to collagen VII through removal of the NC-2 domain , 1995, The Journal of cell biology.

[16]  J. Uitto,et al.  Type VII collagen specifically binds fibronectin via a unique subdomain within the collagenous triple helix. , 1994, The Journal of investigative dermatology.

[17]  J. Uitto,et al.  Cloning of human type VII collagen. Complete primary sequence of the alpha 1(VII) chain and identification of intragenic polymorphisms. , 1994, The Journal of biological chemistry.

[18]  E. Bauer,et al.  Premature termination codons in the type VII collagen gene (COL7A1) underlie severe, mutilating recessive dystrophic epidermolysis bullosa. , 1994, Genomics.

[19]  R. Kramer,et al.  Epidermal growth factor (EGF) promotes human keratinocyte locomotion on collagen by increasing the alpha 2 integrin subunit. , 1993, Experimental cell research.

[20]  R. Burgeson Type VII collagen, anchoring fibrils, and epidermolysis bullosa. , 1993, The Journal of investigative dermatology.

[21]  M Goossens,et al.  Genetic linkage of recessive dystrophic epidermolysis bullosa to the type VII collagen gene. , 1992, The Journal of clinical investigation.

[22]  E. Bauer,et al.  Symposium on Epidermolysis Bullosa: Molecular Biology and Pathology of the Cutaneous Basement Membrane Zone , 1992 .

[23]  J. Uitto,et al.  Molecular biology and pathology of type VII collagen * , 1992, Experimental dermatology.

[24]  E. Bauer,et al.  Human type VII collagen: cDNA cloning and chromosomal mapping of the gene. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Woodley,et al.  Laminin inhibits human keratinocyte migration , 1988, Journal of cellular physiology.

[26]  R. Glanville,et al.  Anchoring fibrils contain the carboxyl-terminal globular domain of type VII procollagen, but lack the amino-terminal globular domain. , 1987, The Journal of biological chemistry.

[27]  N. Morris,et al.  Type VII collagen forms an extended network of anchoring fibrils , 1987, The Journal of cell biology.

[28]  N. Morris,et al.  Large complex globular domains of type VII procollagen contribute to the structure of anchoring fibrils. , 1986, The Journal of biological chemistry.

[29]  N. Morris,et al.  The tissue form of type VII collagen is an antiparallel dimer. , 1986, The Journal of biological chemistry.

[30]  S. Boyce,et al.  Calcium-regulated differentiation of normal human epidermal keratinocytes in chemically defined clonal culture and serum-free serial culture. , 1983, The Journal of investigative dermatology.

[31]  G. Albrecht-Buehler,et al.  The phagokinetic tracks of 3T3 cells , 1977, Cell.

[32]  J. Uitto,et al.  Molecular basis for the dystrophic forms of epidermolysis bullosa: mutations in the type VII collagen gene , 2004, Archives of Dermatological Research.

[33]  J. Uitto,et al.  Molecular basis of dystrophic epidermolysis bullosa: Mutations in the type VII collagen gene (COL7A1) , 1997, Human mutation.

[34]  A. Lin,et al.  Epidermolysis bullosa : basic and clinical aspects , 1992 .

[35]  M. L. Chiu,et al.  Stimulation of thymidine incorporation in keratinocytes by insulin, epidermal growth factor, and placental extract: comparison with cell number to assess growth. , 1988, The Journal of investigative dermatology.